Cereno Scientific presents results at “The International Society on Thrombosis and Hemostasis” in Melbourne
Cereno Scientific has received an accept on their submitted abstract “A New Treatment for Thrombosis Prevention?” at the International Society on Thrombosis and Hemostasis (ISTH) 2019 in Melbourne, Australia. The results will be presented by co-founder Pia Larsson, Ph.D. who has been involved in the research behind the development of the drug candidate CS1. The presentation will take place on July 7 and the abstract will be published on the conference website on June 21.
“ISTH is an important conference within thrombosis and cardiovascular diseases. The conference gives us an opportunity to present our research to key stakeholders within the field of thrombosis,” says Cereno Scientific’s CEO Sten R. Sörensen.
Cereno Scientific received patent approval in Australia for use of drug candidate CS1 earlier in the spring of 2019.
“Therefore, it is pleasing to present our research at this important conference where the world’s leading researchers and companies are represented,” says Cereno Scientific’s CEO Sten R. Sörensen.
About ISTH 2019
At ISTH 2019, thousands of the world’s leading experts on thrombosis, hemostasis and vascular biology come together. Through extensive educational sessions, lectures and networking opportunities, the conference promotes the latest scientific advances and applications to improve patient care worldwide.
About Cereno Scientific AB
Cereno Scientific is developing novel preventive medicine to treat thrombosis-related disease, based on the body’s own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. Cereno Scientific’s drug candidate, CS1, is expected to provide a possibility for an effective prevention of thrombosis and a lower risk for serious bleeding complications than with current blood thinning therapies. CS1 is an innovative controlled release formulation of a known compound, and as such is expected to have a relatively short development time. In parallel with the development of CS1, Cereno Scientific develops CS014, a preclinical phase compound with promising and innovative characteristics in cardiovascular diseases. The Gothenburg-based company is located in AstraZeneca’s BioVenture Hub and is supported by GU Ventures. Cereno Scientific’s B share has been listed on Spotlight Stock market since June 2016 with the ticker CRNO B, ISIN SE0008241558.